Reata Pharmaceuticals (NASDAQ:RETA) Stock Rating Reaffirmed by 888

Reata Pharmaceuticals (NASDAQ:RETA – Free Report)‘s stock had its “reiterates” rating reiterated by analysts at 888 in a research note issued to investors on Wednesday, Benzinga reports. A number of other equities analysts also recently weighed in on the stock. SVB Securities raised shares of Reata Pharmaceuticals from a “market perform” rating to an “outperform” […]

Related Keywords

Wellington ,New Zealand General ,New Zealand ,Blackrock ,Michaeld Wortley ,Andrea Loewen ,Wellington Management Group ,Perceptive Advisors ,Securities Exchange Commission ,Analyst Recommendations For Reata Pharmaceuticals ,News Ratings For Reata Pharmaceuticals Daily ,Reata Pharmaceuticals Inc ,Vanguard Group Inc ,Citigroup ,Hedge Funds Weigh In On Reata Pharmaceuticals ,First Light Asset Management ,Barclays ,Reata Pharmaceuticals ,Blackrock Inc ,Reata Pharmaceuticals Price Performance ,Free Report ,Exchange Commission ,Management Group ,Light Asset Management ,Reata Pharmaceuticals Daily ,Nasdaq Reta ,Greta ,Medical ,Reiterated Rating ,888 Holdings Plc ,